Close Menu
Advertisement
Subscribe
[the_ad id="32629"]
Acute Lymphoblastic Leukemia

The outcomes of Checkmate 142 in mCRC

Editor By No Comments1 Min Read

John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at Annual Meeting 2018.

Share.

Related Posts